



DepoCyt® (cytarabine liposome) – Drug Discontinuation

- On June 29, 2017, [Pacira Pharmaceuticals announced](#) the permanent discontinuation of [DepoCyt \(cytarabine liposome\)](#) injection due to persistent technical issues related to the product's manufacturing process.
 - However, this decision does not impact the quality or safety of any product already distributed to customers or patients.
- DepoCyt is indicated for the intrathecal treatment of lymphomatous meningitis.
- DepoCyt carries a boxed warning regarding chemical arachnoiditis.
- Available supplies of DepoCyt may continue to be distributed until existing product is gone.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.